Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Mezzapelle, Rosanna ^a   Rrapaj, Eltjona ^a,l   Gatti, Elena ^a   Ceriotti, Chiara ^a   De Marchis, Francesco ^a   Preti, Alessandro ^b   Spinelli, Antonello E ^a   Perani, Laura ^a   Venturini, Massimo ^a   Valtorta, Silvia ^a,c   Moresco, Rosa Maria ^a,d   Pecciarini, Lorenza ^a   Doglioni, Claudio ^a,k   Frenquelli, Michela ^a   Crippa, Luca ^e   Recordati, Camilla ^f   Scanziani, Eugenio ^f,g   De Vries, Hilda ^h   Berns, Anton ^h   Frapolli, Roberta ⁱ   Boldorini, Renzo ^j   D'Incalci, Maurizio ⁱ   Bianchi, Marco E ^a,k   Crippa, Massimo P ^a   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b HMGBiotech Srl   (Italy)

^c INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e ISTOVET ^*  (Italy)

^f Fondazione Filarete   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^j MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^k VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^l UNIVERSITY OF EASTERN PIEDMONT   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; GEMCITABINE; HIGH MOBILITY GROUP B1 PROTEIN; PEMETREXED;

ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; FEMALE; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGY; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOCOMPETENCE; LUNG NEOPLASMS; MESOTHELIOMA; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PEMETREXED; SURVIVAL ANALYSIS;

EID: 84960891457     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22850     Document Type: Article

References (32)

1. Carbone, M. et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 227, 44-58 (2012).
2. Carbone, M. et al. BAP1 and cancer. Nat Rev Cancer 13, 153-159 (2013).
3. Husain, A. N. et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 137, 647-667 (2013).
4. Rose, A. H. et al. Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors. Am J Pathol. 184, 1041-1049 (2014).
5. Davidson, B. Prognostic factors in malignant pleural mesothelioma. Hum Pathol. 46, 789-804 (2015).
6. Fennell, D. A., Gaudino, G., O'Byrne, K. J., Mutti, L. & van Meerbeeck, J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 5, 136-147 (2008).
7. Carbone, M. & Yang, H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 18, 598-604 (2012).
8. Panou, V. et al. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. 41, 486-495 (2015).
9. Goudar, R. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma. Ther Clin Risk Manag. 4, 205-211 (2008).
10. Jube, S. et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72, 3290-3301 (2012).
11. Yang, H. et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107, 12611-12616 (2010).
12. Vénéreau, E., Ceriotti, C. & Bianchi, M. E. DAMPs from Cell Death to New Life. Front Immunol. 18, 422 (2015).
13. Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12, 860-875 (2012).
14. Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J. & Robinson, B. W. Establishment of a murine model of malignant mesothelioma. Int J Cancer 52, 881-886 (1992).
15. Bielefeldt-Ohmann, H. et al. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother. 40, 241-250 (1995).
16. Crisanti, M. C. et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 8, 2221-2231 (2009).
17. Darrasse-Jèze, G. et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest. 19, 2648-2662 (2009).
18. Bergot, A. S. et al. Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells. Cancer Gene Ther. 17, 645-654 (2010).
19. Veltman, J. D. et al. Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. J Biomed Biotechnol. 2010, 798467 (2010).
20. Ireland, D. J., Kissick, H. T. & Beilharz, M. W. The Role of Regulatory T Cells in Mesothelioma. Cancer Microenviron. 5, 165-172 (2012).
21. Predina, J. D. et al. A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer Biol Ther. 13, 745-755 (2012).
22. Fisher, S. A. et al. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. J Transl Med. 12, 245 (2014).
23. Relan, V. et al. Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One 8, e58132 (2013).
24. Bepler, G. et al. Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37, 158-171 (1988).
25. Orengo, A. M. et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. 13, 527-534 (1999).
26. Philippeaux, M. M. et al. Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis. Histochem Cell Biol. 122, 249-260 (2004).
27. Kobayashi, M., Takeuchi, T. & Ohtsuki, Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res. 28, 197-208 (2008).
28. Cottone, L. et al. Evaluation of the role of tumor-associated macrophages in an experimental model of peritoneal carcinomatosis using (18)F-FDG PET. J Nucl Med. 52, 1770-1777 (2011).
29. Fassina, A. et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 25, 86-99 (2012).
30. Marchevsky, A. M. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 132, 397-401 (2008).
31. Vandermeers, F. et al. Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma. Clin. Can. Res. 15, 2818-2828. (2009).
32. Rudd, R. M. Malignant mesothelioma. Br Med Bull. 93, 105-123 (2010).